World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
72
Citations
25900
World Ranking
2176
National Ranking
1056

Paul R. Clapham publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Paul R. Clapham sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 156 publications — 18th percentile

18% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Paul R. Clapham D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Paul R. Clapham sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 72 D-Index — 56th percentile

56% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Paul R. Clapham is affiliated with the University of Massachusetts Chan Medical School in the United States. Their research spans multiple fields, including Immunology and Microbiology and Medicine, with a particular focus on several specialized subfields such as Virology, Industrial and Manufacturing Engineering, Molecular Biology, Radiology, Nuclear Medicine and Imaging, and Strategy and Management.

Their recent publications reflect a diverse range of topics, highlighting their involvement in both biomedical research and sustainable industrial practices. Notably, their works include:

  • Precursor considerations for new circular economy business models, 2022, published in IOP Conference Series Earth and Environmental Science
  • Implications of the 375W mutation for HIV-1 tropism and vaccine development, 2022, published in bioRxiv (Cold Spring Harbor Laboratory)
  • Implications of the 375W mutation for HIV-1 tropism and vaccine development, 2024, published in Journal of Virology

These publications demonstrate their active engagement with the study of HIV research and treatment, as well as vaccines and immunoinformatics approaches. Additionally, Paul R. Clapham has contributed to research on sustainable supply chain management, recycling and waste management techniques, and sustainable industrial ecology.

Their frequent co-authors include:

  • Odette Verdejo-Torres
  • Tania Vargas-Pavia
  • Syeda Urooj Fatima
  • Maria José Duenas-Decamp
  • Usha Iyer-Raniga

Their work has been disseminated through various publication venues such as bioRxiv (Cold Spring Harbor Laboratory), IOP Conference Series Earth and Environmental Science, and the Journal of Virology.

Paul R. Clapham's main topics of research cover a broad range of scientific and technical areas, including:

  • HIV Research and Treatment
  • Vaccines and Immunoinformatics Approaches
  • Monoclonal and Polyclonal Antibodies Research
  • Sustainable Supply Chain Management
  • Recycling and Waste Management Techniques
  • Sustainable Industrial Ecology
  • Immune Cell Function and Interaction

This combination of expertise situates Paul R. Clapham at the intersection of biomedical science and sustainable industrial practices, providing an interdisciplinary perspective on both health and environmental challenges through their ongoing academic contributions.

Best Publications

  • The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus

    Angus G. Dalgleish;Peter C. L. Beverley;Paul R. Clapham;Dorothy H. Crawford

  • The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain.

    Paul Jay Maddon;Angus G. Dalgleish;J.Steven McDougal;Paul R. Clapham

  • Potent Inhibition of HIV-1 Infectivity in Macrophages and Lymphocytes by a Novel CCR5 Antagonist

    Graham Simmons;Paul R. Clapham;Laurent Picard;Robin E. Offord

  • CD4-Independent Infection by HIV-2 Is Mediated by Fusin/CXCR4

    Michael J Endres;Paul R Clapham;Mark Marsh;Ména Ahuja

  • Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients.

    Robin A. Weiss;Paul R. Clapham;Rachanee Cheingsong-Popov;Angus G. Dalgleish

  • A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus

    Thomas N. Kledal;Mette M. Rosenkilde;Florence Coulin;Graham Simmons

  • Aminooxypentane-RANTES Induces CCR5 Internalization but Inhibits Recycling: A Novel Inhibitory Mechanism of HIV Infectivity

    Matthias Mack;Bruno Luckow;Peter J. Nelson;Josef Cihak

  • Identification of the Residues in Human CD4 Critical for the Binding of HIV

    J Arthos;K C Deen;M A Chaikin;J A Fornwald

  • Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells

    Paul R. Clapham;Jonathan N. Weber;Denise Whitby;Kenneth McIntosh;Kenneth McIntosh

  • Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry.

    G Simmons;D Wilkinson;J D Reeves;M T Dittmar

  • Cell surface receptors, virus entry and tropism of primate lentiviruses.

    Paul R. Clapham;Áine McKnight

  • Variable and conserved neutralization antigens of human immunodeficiency virus

    Robin A. Weiss;Paul R. Clapham;Jonathan N. Weber;Angus G. Dalgleish

  • Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by Simian immunodeficiency virus.

    Paul R. Clapham;Dominique Blanc;Robin A. Weiss

  • HIV-1 receptors and cell tropism.

    Paul R Clapham;Áine McKnight

  • The BBXB Motif of RANTES Is the Principal Site for Heparin Binding and Controls Receptor Selectivity

    Amanda E.I. Proudfoot;Sarah Fritchley;Frédéric Borlat;Jeffrey P. Shaw

  • HIV infection does not require endocytosis of its receptor, CD4.

    Paul Jay Maddon;J. Steven McDougal;Paul R. Clapham;Angus G. Dalgleish

  • The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion?

    Gary J. Clements;Molly J. Price-Jones;Paul E. Stephens;Christopher Sutton

  • KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells

    Johnny T. Stine;Christi Wood;Mark Hill;Angela Epp

  • Human T‐cell leukemia virus type I: Induction of syncytia and inhibition by patients' sera

    Károly Nagy;Paul Clapham;Rachanee Cheingsong-Popov;Robin A. Weiss

  • Biological Analysis of Human Immunodeficiency Virus Type 1 R5 Envelopes Amplified from Brain and Lymph Node Tissues of AIDS Patients with Neuropathology Reveals Two Distinct Tropism Phenotypes and Identifies Envelopes in the Brain That Confer an Enhanced Tropism and Fusigenicity for Macrophages

    Paul J. Peters;Jayanta Bhattacharya;Samantha Hibbitts;Matthias T. Dittmar

Frequent Co-Authors

Áine McKnight
Áine McKnight Queen Mary University of London
Robin A. Weiss
Robin A. Weiss University College London
Amanda E. I. Proudfoot
Amanda E. I. Proudfoot Merck (Germany)
Katherine Luzuriaga
Katherine Luzuriaga University of Massachusetts Chan Medical School
Shan Lu
Shan Lu University of Massachusetts Chan Medical School
Mark Marsh
Mark Marsh University College London
Angus G. Dalgleish
Angus G. Dalgleish St George's, University of London
Christine A. Power
Christine A. Power Merck Serono (Italy)
Richard Axel
Richard Axel Columbia University
Peter Simmonds
Peter Simmonds University of Oxford

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to various advanced healthcare roles, especially in nursing and specialized practice areas. For those interested in expanding their clinical expertise, transitioning from an FNP to acute care certification can be a strategic move. This shift allows nurse practitioners to work with critically ill patients, enhancing their clinical impact and job prospects.

Many students seek flexible learning options, which is why accelerated NP programs have gained popularity. These programs enable students to fast-track their education while maintaining quality and depth needed for demanding healthcare roles. Additionally, non-nurses looking to enter the healthcare field can explore the best online RN programs for non nurses, offering a solid foundation in nursing without prior clinical experience.

Financially, pursuing advanced degrees like a Doctor of Nursing Practice (DNP) can be rewarding. Understanding how much does a DNP make across different states helps prospective students make informed career decisions based on regional salary variations and healthcare demands.

Exploring these pathways ensures that students and professionals in immunology and healthcare can find tailored online programs and certifications that align with their career goals and lifestyle needs.

Learn more about fnp to acute care certification, discover top accelerated np programs, consider best online rn programs for non nurses, and understand how much does a dnp make in your state.

Best Scientists Citing Paul R. Clapham

Trending Scientists

Recently Published Articles